Cerebral Injury and Impaired Brain Metabolism in Patients With Left Ventricular Assist Device and Chronic Heart Failure —An Interdisciplinary Cognition, Blood‐Based Biomarker and Brain Metabolism Assessment

Martin S. Jungclaus; Lorenzo Barba; Markus Otto; Florian Wilke; Arjang Ruhparwar; Jasmin Sarah Hanke; Jan Dieter Schmitto; Dominik Berliner; Thorsten Derlin; Rudolf Alexander Werner; Frank Michael Bengel; Karin Weißenborn; Kai G. Kahl; Julia Hoffmeister; Georg Berding; Hans Worthmann; Desiree Weiberg; Maria Magdalena Gabriel

doi:10.1161/jaha.125.043727

Cerebral Injury and Impaired Brain Metabolism in Patients With Left Ventricular Assist Device and Chronic Heart Failure —An Interdisciplinary Cognition, Blood‐Based Biomarker and Brain Metabolism Assessment | ResearchHub - ResearchHub

Enriched recordOpen access

Cerebral Injury and Impaired Brain Metabolism in Patients With Left Ventricular Assist Device and Chronic Heart Failure —An Interdisciplinary Cognition, Blood‐Based Biomarker and Brain Metabolism Assessment

Martin S. Jungclaus, Lorenzo Barba, Markus Otto, Florian Wilke, Arjang Ruhparwar, Jasmin Sarah Hanke, Jan Dieter Schmitto, Dominik Berliner, Thorsten Derlin, Rudolf Alexander Werner, Frank Michael Bengel, Karin Weißenborn, Kai G. Kahl, Julia Hoffmeister, Georg Berding, Hans Worthmann, Desiree Weiberg, Maria Magdalena Gabriel

Journal of the American Heart Association2026doi:10.1161/jaha.125.043727

Citation graph

Abstract

Background Chronic heart failure is linked to cognitive dysfunction. Left ventricular assist devices (LVAD) potentially ameliorate cognition, but continuous flow profiles might result in long‐term progression. In this cross‐sectional pilot study, we aimed to investigate the association between LVAD therapy and neuronal impairment measured by cognitive performance, blood‐based biomarkers of neuronal injury and 18 F‐fluorodeoxyglucose‐positron emission tomography/computed tomography‐derived brain metabolism. Methods We prospectively enrolled 19 patients with LVAD and 13 patients with advanced chronic heart failure receiving best medical treatment. Cognitive performance was assessed using the Montreal Cognitive Assessment and Frontal Assessment Battery. Serum levels of NfL (neurofilament light chain), pTau181 (phosphorylated Tau protein at threonine 181), and GFAP (glial fibrillary acidic protein) were measured by immunoassay. Brain metabolism was assessed using 18 F‐fluorodeoxyglucose‐positron emission tomography/computed tomography by statistical parametric mapping analyses compared with 16 healthy controls ( P Results Of all patients, 69% showed cognitive dysfunction, 5 patients had evidence for frontotemporal impairment. Median neurochemical biomarker concentrations were elevated in the whole cohort (NfL 45.7 pg/mL [26.9–80.2]; pTau181 23.1 pg/mL [18.1–40.1]; GFAP 191.3 pg/mL [126.3–251.7]). Both groups did not differ regarding cognitive performance and biomarker levels. The uncorrected statistical parametric mapping analyses indicated frontotemporally accentuated hypometabolism in both groups compared with healthy controls. Patients with LVAD revealed more hypometabolic volumes in single‐subject analyses (LVAD 1.03 mL (0–7.34); chronic heart failure 0 mL (0–0.01), P Conclusions In this exploratory study, patients with chronic heart failure and patients with LVAD exhibited impaired cognitive performance and elevated biomarker levels of neuronal injury. 18 F‐fluorodeoxyglucose‐positron emission tomography/computed tomography results of uncorrected thresholds suggested subtle frontal hypometabolism. Neurochemical biomarkers and 18 F‐fluorodeoxyglucose‐positron emission tomographyappear promising for further investigation of cerebral health in patients with heart failure.

External reference records

10.1002/ejhf.1236

10.7759/cureus.9671

10.5603/cj.a2021.0172

10.1016/j.cardfail.2017.04.007

10.1002/brb3.2176

10.1002/ehf2.14599

10.3389/fcvm.2023.1181979

10.1016/j.jacc.2017.01.022

10.1113/jp278864

10.1016/j.jaclp.2022.09.003

10.1097/jcn.0000000000000709

10.1007/s11748-018-0947-5

10.1016/j.jchf.2021.05.016

10.1016/j.healun.2015.05.015

10.1016/j.healun.2011.10.012

10.1016/j.amjcard.2022.02.041

10.1161/circoutcomes.115.001856

10.1016/j.healun.2019.11.019

10.1161/jaha.117.005955

10.1007/s12975-021-00935-z

10.1097/mat.0000000000001317

10.1016/j.healun.2020.01.1337

10.1113/jp276729

10.1007/s00259-021-05603-w

10.1016/j.jcmg.2019.04.024

10.1097/mat.0000000000000552

10.1007/s00259-020-04930-8

10.2967/jnumed.119.237628

10.1007/s00063-020-00685-0

10.1007/s10237-022-01686-y

10.1038/s41598-023-45110-6

10.1159/000517454

10.1161/strokeaha.118.022967

10.1056/nejmoa1900486

10.1111/j.1532-5415.2005.53221.x

10.1016/j.hrtlng.2014.05.011

10.1007/s12350-020-02258-2

10.1212/wnl.55.11.1621

10.1097/jcn.0000000000000265

10.1001/jamaneurol.2022.5250

External cited-by records

10.1006/nimg.2001.0978

10.1006/nimg.2001.0978 · doi-reference

10.1007/978-981-19-7580-6

10.1007/978-981-19-7580-6 · doi-reference

10.1007/s00415-013-6929-8

10.1007/s00415-013-6929-8 · doi-reference

10.1177/0145482x1010400606

10.1177/0145482x1010400606 · doi-reference

10.1016/j.healun.2011.01.717

10.1016/j.healun.2011.01.717 · doi-reference

10.1212/wnl.0000000000002923

10.1212/wnl.0000000000002923 · doi-reference

10.1177/25424823251314392

10.1177/25424823251314392 · doi-reference

10.1038/s41467-025-57144-7

10.1038/s41467-025-57144-7 · doi-reference

10.1002/alz.13859

10.1002/alz.13859 · doi-reference

10.1111/ene.16581

10.1111/ene.16581 · doi-reference

10.1038/s41582-021-00616-3

10.1038/s41582-021-00616-3 · doi-reference

10.1002/trc2.12034

10.1002/trc2.12034 · doi-reference

10.1007/s10571-014-0127-9

Cerebral Injury and Impaired Brain Metabolism in Patients With Left Ventricular Assist Device and Chronic Heart Failure —An Interdisciplinary Cognition, Blood‐Based Biomarker and Brain Metabolism Assessment

Referenced works

Cited by

External reference records

External cited-by records